Royce & Associates LP Fate Therapeutics Inc Transaction History

Royce & Associates LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$3.54 - $8.35 $226,273 - $533,723	-63,919 Reduced 59.56%	43,399 $318,000
Q4 2023 Feb 12, 2024	BUY	$1.65 - $3.94 $127,015 - $303,297	76,979 Added 253.73%	107,318 $401,000
Q3 2023 Nov 09, 2023	BUY	$2.02 - $5.04 $61,284 - $152,908	30,339 New	30,339 $64,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.